In a recent report on NeurologyAdvisor, there is a talk about how the addition of Cannabidiol into a patient’s treatment plan might affect the drug levels from other antiepileptic drugs in the treatment of Refractory Epilepsy, also termed as Epilepsy which cannot be controlled with drugs. This study was apparently published from Epilepsia. You can read more about Epilepsy on CuraHOPE here.
Cannabidol might affect the drug levels of other anti-epileptic drugs in Refractory Epilepsy
The study was conducted by Tyler E. Gaston, MD, of the University of Alabama at Birmingham Epilepsy Center, and colleagues on a total of about 80 individuals, with about half of them being children and the other half being adults. Most of the participants were sufferers of Epilepsy who displayed drug resistance to existing Epilepsy drugs. We are wondering, if they are resistant to the drugs, should they still be taking the drugs?
Looking at how the study was conducted, we felt worry. We hope that the participants are well compensated for this study. What was concerning about the study was the fact that dosages of Cannabidol (CBD) of the participants were adjusted based on how well they tolerate the dosages, their responses or instances where seizures worsen.
What is the significance of this study?
Basically, the study was intended to be helpful in illustrating if CBD can improve the effectiveness of other antiepileptic drugs or is it detrimental to sufferers. The results however, were not completely illuminating as it found that increasing doses of CBD is correlated with decreased serum levels of clobazam and increased serum levels of topiramate, rufinamide, and N-desmethylclobazam. However, given that the various drugs mentioned (clobazam, topiramate, rufinamide and N-desmethylclobazam) are all anticonvulsants (drugs which treat epilepsy and attempt to prevent seizures), the use of CBD is not exactly very clear.
What can be done better?
I feel that with current advancements in medical science, we should be more stringent on medical tests and research. Subjectivity should be eliminated as much as possible, and monitoring should be 247. While costs will increase, perhaps it might be more effective than diversifying research.
Open sourcing research is the future of medical science, but companies and people might not be too open to that as it might decrease the potential for profits to be made. We will fight continuously for the model, and we do not have to be the executor, we are happy being the torch bearer.